| MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients AA Brandes, E Franceschi, A Tosoni, V Blatt, A Pession, G Tallini, ... Journal of Clinical Oncology 26 (13), 2192-2197, 2008 | 941 | 2008 |
| Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034 MJ van den Bent, AA Brandes, R Rampling, MCM Kouwenhoven, JM Kros, ... Journal of Clinical Oncology 27 (8), 1268, 2009 | 619 | 2009 |
| Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status AA Brandes, A Tosoni, E Franceschi, G Sotti, G Frezza, P Amistà, ... J Clin Oncol 27 (8), 1275-1279, 2009 | 371 | 2009 |
| Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology AA Brandes, A Tosoni, F Spagnolli, G Frezza, M Leonardi, F Calbucci, ... Neuro-oncology 10 (3), 361-367, 2008 | 321 | 2008 |
| Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) AA Brandes, A Tosoni, G Cavallo, R Bertorelle, V Gioia, E Franceschi, ... British journal of cancer 95 (9), 1155-1160, 2006 | 282 | 2006 |
| Glioblastoma in adults AA Brandes, A Tosoni, E Franceschi, M Reni, G Gatta, C Vecht Critical reviews in oncology/hematology 67 (2), 139-152, 2008 | 257 | 2008 |
| Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection C Agostini, F Calabrese, F Rea, M Facco, A Tosoni, M Loy, G Binotto, ... The American journal of pathology 158 (5), 1703-1711, 2001 | 252 | 2001 |
| Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status AA Brandes, E Franceschi, A Tosoni, F Benevento, L Scopece, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 250 | 2009 |
| Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) E Franceschi, G Cavallo, S Lonardi, E Magrini, A Tosoni, D Grosso, ... British journal of cancer 96 (7), 1047-1051, 2007 | 231 | 2007 |
| Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent … AA Brandes, A Tosoni, G Cavallo, M Reni, E Franceschi, L Bonaldi, ... Journal of clinical oncology 24 (29), 4746-4753, 2006 | 218 | 2006 |
| Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas L Trentin, A Cabrelle, M Facco, D Carollo, M Miorin, A Tosoni, P Pizzo, ... Blood 104 (2), 502-508, 2004 | 192 | 2004 |
| The pathogenesis and treatment of brain metastases: a comprehensive review A Tosoni, M Ermani, AA Brandes Critical reviews in oncology/hematology 52 (3), 199-215, 2004 | 188 | 2004 |
| Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments AA Brandes, E Franceschi, A Tosoni, ME Hegi, R Stupp Clinical cancer research 14 (4), 957-960, 2008 | 168 | 2008 |
| Long‐term results of a prospective study on the treatment of medulloblastoma in adults AA Brandes, E Franceschi, A Tosoni, V Blatt, M Ermani Cancer 110 (9), 2035-2041, 2007 | 168 | 2007 |
| How effective is BCNU in recurrent glioblastoma in the modern era?: A phase II trial AA Brandes, A Tosoni, P Amista, L Nicolardi, D Grosso, F Berti, M Ermani Neurology 63 (7), 1281-1284, 2004 | 163 | 2004 |
| First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia AA Brandes, U Basso, M Reni, F Vastola, A Tosoni, G Cavallo, L Scopece, ... Journal of Clinical Oncology 22 (9), 1598-1604, 2004 | 142 | 2004 |
| Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo … AA Brandes, A Tosoni, U Basso, M Reni, F Valduga, S Monfardini, ... Journal of clinical oncology 22 (23), 4779-4786, 2004 | 140 | 2004 |
| O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for … AA Brandes, E Franceschi, A Tosoni, S Bartolini, A Bacci, R Agati, ... Neuro-oncology 12 (3), 283-288, 2010 | 139 | 2010 |
| Expression of 19 microRNAs in glioblastoma and comparison with other brain neoplasia of grades I–III M Visani, D de Biase, G Marucci, S Cerasoli, E Nigrisoli, MLB Reggiani, ... Molecular oncology 8 (2), 417-430, 2014 | 115 | 2014 |
| Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo … AA Brandes, A Tosoni, E Franceschi, V Blatt, A Santoro, M Faedi, ... Cancer chemotherapy and pharmacology 64, 769-775, 2009 | 111 | 2009 |
